Health TrialsbyHealthPanel

Zinc Incorporated Bovine Derived- Hydroxyappatite Xenograft in Immediately Placed Implant

ConditionsImplantZinc Status
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21-50
SponsorSuez Canal University

About this trial

The aim of this study is to evaluate Clinical and radiographic effect of zinc incorporated bovine derived hydroxyapatite xenograft and bovine hydroxyapatite xenograft alone for immediately placed implant

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Adult(male or female) patients between the ages of 21 -50 years who requiring the replacement of one or more non-restorable teeth in the mandible which will be indicated for extraction.

Adequate bone dimensions at the implant site with ridge width of at least 6 mm, the availability of at least 3mm of sound subapical bone, the presence of an intact labial bone plate, and no evidance of periapical infection on cone beam computed tomography or clinically

The peri-implant gaps larger than 1.5 mm will be included.

All patients will be physically healthy with no medical history of any systemic disease.

Disqualifiers

Smokers.

Patients with para functional habits such as bruxism and clenching

Poorly controlled systemic diseases which preclude local anesthesia or surgical procedures

Patients undergoing chemotherapy or radiotherapy and immuno-compromised patients.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Immediate implant with bovine drived hydroxyapatite xenograft.

    Procedure/Surgery

    patients will undergo immediate implant with bovine drived hydroxyapatite xenograft.

  • immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft

    Procedure/Surgery

    patients will undergo immediate implant with zinc incorporated bovine drived hydroxyapatite xenograft

Treatment groups

16 Participants
are divided into 2 treatment groups
Group A: Group I (control)Experimental treatment 1 intervention
Group B: Group II (Test group)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Marginal bone loss

Marginal bone loss was defined as the distance from the implant platform to the alveolar crest.

Time frame
9 months

Secondary outcomes

1

densitometric gray scale value to measure bone density

Time frame
9 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Suez Canal University

Lead sponsor

Source ClinicalTrials.gov
Apply now